Goldman Sachs downgraded Rocket Pharmaceuticals (RCKT) to Sell from Neutral with a price target of $2, down from $13.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals: Buy Rating Affirmed Amid Strategic Adjustments and Financial Resilience
- Rocket Pharmaceuticals price target lowered to $17 from $46 at Chardan
- Rocket Pharmaceuticals price target lowered to $8 from $30 at BMO Capital
- Rocket Pharmaceuticals price target lowered to $9 from $32 at BofA
- Hold Rating for Rocket Pharmaceuticals Amid Safety Concerns and Financial Uncertainties